JB Chem To Form SBUs For Neurology, Oncology

Mumbai, Nov 6: | Updated: Nov 7 2003, 05:30am hrs
JB Chemicals & Pharmaceuticals is planning to set up two new strategic business units (SBUs) to focus on neurology and oncology. The company has identified the products to be launched but has not finalised them, sources said.

The SBUs to be operational from December this year, would have a field force of around 150 representatives.

Commenting on the companys plans, JB Chemicals & Pharmaceuticals chairman and managing director JB Mody in a release said, "Our vision is to create a strong base in niche segments in neuro-psychiatry and oncology segments for a sustainable long term competitive advantage."

Currently CNS segment (neuro-psychiatry) is growing at 15 per cent per annum with a market size of Rs 600 crore as per AC Nielsen ORG MARG, while oncology is growing at 40 per cent with a market size of Rs 200 crore.

The neuro-psychiatry and speciality products division will be christened Zephyr. The division will also have products focussing on gastroenterology and urology segments.

The company also plans to create a franchisee division, christened Uniquest. JB Chemicals will manufacture and supply the products and promotional inputs to franchisees to promote and market the products through their field force, a JB Chemicals release said. The entire operations will be controlled by the company through one national head of marketing based in Mumbai.

The company has 11 state-of-the-art manufacturing facilities at four locations in India and has reported a net profit of Rs 19.1 crore on a turnover of Rs 96.06 crore for the second quarter ended September 30, 2003.